Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1519634 | 0.83 | APP (0.44) | DPP4APPFFAR1 | |
| SCHEMBL4923610 | 0.83 | AAK1 (0.38) | AAK1LTA4H | |
| SCHEMBL11221171 | 0.82 | DPP4 (0.37) | DPP4APPSLC7A5FFAR1AAK1 | |
| SCHEMBL28055241 | 0.82 | DPP4 (0.37) | DPP4APPSLC7A5FFAR1AAK1 | |
| SCHEMBL28304220 | 0.78 | DPP4 (0.33) | DPP4FFAR1CASP3 | |
| SCHEMBL1519829 | 0.77 | FFAR1 (0.40) | DPP4APPFFAR1AAK1 | |
| SCHEMBL1521461 | 0.76 | LMNA (0.40) | FFAR1 | |
| SCHEMBL12971465 | 0.74 | DPP4 (0.39) | DPP4FFAR1 | |
| SCHEMBL744345 | 0.74 | DPP4 (0.39) | DPP4FFAR1 | |
| SCHEMBL743074 | 0.74 | DPP4 (0.39) | DPP4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107286164-B | Application of compound in preparation of sitagliptin and method for preparing sitagliptin | 武汉臻智生物科技有限公司 | 2021-08-03 | — | — | CN | claimed |
| CN-107286164-B | Application of compound in preparation of sitagliptin and method for preparing sitagliptin | 武汉臻智生物科技有限公司 | 2021-08-03 | — | — | CN | disclosed |
| CN-105331651-B | The enzyme-chemically preparation method of sitagliptin and its intermediate | 尚科生物医药（上海）有限公司 | 2018-11-13 | — | — | CN | disclosed |
| CN-107286164-A | Purposes of the compound in sitagliptin is prepared and the method for preparing sitagliptin | 武汉臻智生物科技有限公司 | 2017-10-24 | — | — | CN | disclosed |
| EP-2736909-B1 | PROCESS FOR THE PREPARATION OF SITAGLIPTIN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | FARMA GRS D O O (SI) | 2017-03-29 | — | — | EP | disclosed |
| CN-104016993-B | A kind of compound suppressing DPP-IV and intermediate thereof | 成都先导药物开发有限公司 | 2016-09-07 | — | — | CN | disclosed |
| EP-2736909-A1 | PROCESS FOR THE PREPARATION OF SITAGLIPTIN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | Farma GRS, d.o.o. (SI) | 2014-06-04 | — | — | EP | disclosed |
| WO-2013013833-A1 | PROCESS FOR THE PREPARATION OF SITAGLIPTIN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | FARMA GRS, D.O.O. (SI) | 2013-01-31 | — | — | WO | disclosed |
| US-7820666-B2 | Tetrahydrotriazolopyrazine derivatives and uses thereof | CONCERT PHARMACEUTICALS, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20080280913-A1 | TETRAHYDROTRIAZOLOPYRAZINE DERIVATIVES AND USES THEREOF | CONCERT PHARMACEUTICALS, INC. | 2008-11-13 | — | — | US | disclosed |
| US-20070197522-A1 | Dpp-iv inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197522-A1 | Dpp-iv inhibitors | DPP7, DPP4, DPP3 | DPP4 2/4885APP 2076/4885SLC7A5 776/4885 |
| US-20080280913-A1 | TETRAHYDROTRIAZOLOPYRAZINE DERIVATIVES AND USES THEREOF | DPP4, DPP3, DPP7 | DPP4 1/4885APP 520/4885SLC7A5 1643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.